Ghost Tree Capital, LLC
- SEC CIK
- 0001595851
- Latest filing
- Nov 14, 2024
Holdings in Q2 2024
Holdings as of Jun 30, 2024, filed Aug 14, 2024. Long positions only; changes compare share counts with Q1 2024.
- Positions
- 59
- −6 vs. Q1 2024
- Portfolio value
- $287.4M
- −$23.7M (−7.6%) vs. Q1 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CTMXCytomX Therapeutics, Inc. | COM | 300,000 | $366.0K | 0.1% | −300,000−50.0% | Reduced | History |
| ANTXAN2 Therapeutics, Inc. | COM | 219,331 | $471.6K | 0.2% | 00.0% | Unchanged | History |
| NTLAIntellia Therapeutics, Inc. | COM | 25,000 | $559.5K | 0.2% | 00.0% | Unchanged | History |
| RVNCRevance Therapeutics, Inc. | COM | 225,000 | $578.3K | 0.2% | −225,000−50.0% | Reduced | History |
| PTCTPTC Therapeutics, Inc. | COM | 19,000 | $581.0K | 0.2% | +19,000 | New | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 375,000 | $607.5K | 0.2% | −300,000−44.4% | Reduced | History |
| MGNXMacrogenics Inc | COM | 150,000 | $637.5K | 0.2% | +150,000 | New | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 10,000 | $684.9K | 0.2% | +10,000 | New | History |
| SGMTSagimet Biosciences Inc. | COM SER A | 225,000 | $769.5K | 0.3% | 00.0% | Unchanged | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 35,000 | $909.6K | 0.3% | 00.0% | Unchanged | History |
| WVEWave Life Sciences, Inc. | SHS | 200,000 | $998.0K | 0.3% | +200,000 | New | History |
| ATYRaTYR PHARMA INC | COM NEW | 800,000 | $1.25M | 0.4% | +200,000+33.3% | Added | History |
| PRQRProQR Therapeutics N.V. | SHS EURO | 900,000 | $1.49M | 0.5% | +900,000 | New | History |
| ANNXAnnexon, Inc. | COM | 310,000 | $1.52M | 0.5% | +310,000 | New | History |
| KRYSKrystal Biotech, Inc. | COM | 8,500 | $1.56M | 0.5% | −5,500−39.3% | Reduced | History |
| ELEVElevation Acquisition Group Inc. | COM | 600,000 | $1.62M | 0.6% | +350,000+140.0% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 33,200 | $1.80M | 0.6% | +13,200+66.0% | Added | History |
| RGNXREGENXBIO Inc. | COM | 170,000 | $1.99M | 0.7% | +50,000+41.7% | Added | History |
| ARVNArvinas, Inc. | COM | 75,000 | $2.00M | 0.7% | +35,000+87.5% | Added | History |
| JANXJanux Therapeutics, Inc. | COM | 50,000 | $2.09M | 0.7% | +50,000 | New | History |
| NGNENeurogene Inc. | COM | 70,000 | $2.55M | 0.9% | +45,000+180.0% | Added | History |
| CABACabaletta Bio, Inc. | COM | 370,899 | $2.77M | 1.0% | −4,101−1.1% | Reduced | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 1,250,000 | $2.80M | 1.0% | +300,000+31.6% | Added | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 300,000 | $3.07M | 1.1% | 00.0% | Unchanged | History |
| NUVBNuvation Bio Inc. | COM CL A | 1,150,000 | $3.36M | 1.2% | +1,150,000 | New | History |
| KRROKorro Bio, Inc. | COM | 100,000 | $3.39M | 1.2% | +100,000 | New | History |
| BBIOBridgeBio Pharma, Inc. | COM | 140,000 | $3.55M | 1.2% | −35,000−20.0% | Reduced | History |
| ACADAcadia Pharmaceuticals Inc | COM | 225,000 | $3.66M | 1.3% | 00.0% | Unchanged | History |
| ENGNenGene Therapeutics Inc. | COM | 420,331 | $3.96M | 1.4% | +220,331+110.2% | Added | History |
| REPLReplimune Group, Inc. | COM | 450,000 | $4.05M | 1.4% | −200,000−30.8% | Reduced | History |
| TNYATenaya Therapeutics, Inc. | COM | 1,350,000 | $4.18M | 1.5% | +575,000+74.2% | Added | History |
| SVRASavara Inc | COM | 1,050,876 | $4.24M | 1.5% | −549,124−34.3% | Reduced | History |
| BPMCBlueprint Medicines Corp | COM | 40,000 | $4.31M | 1.5% | −32,761−45.0% | Reduced | History |
| INSMINSMED Inc | COM PAR $.01 | 65,000 | $4.36M | 1.5% | −85,000−56.7% | Reduced | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 117,388 | $4.82M | 1.7% | −7,612−6.1% | Reduced | History |
| VKTXViking Therapeutics, Inc. | COM | 95,000 | $5.04M | 1.8% | +21,998+30.1% | Added | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 135,000 | $5.18M | 1.8% | +5,000+3.8% | Added | History |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 22,500 | $5.47M | 1.9% | −37,500−62.5% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 250,237 | $5.88M | 2.0% | +150,237+150.2% | Added | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 550,000 | $5.95M | 2.1% | +350,000+175.0% | Added | History |
| RZLTRezolute, Inc. | COM NEW | 1,421,501 | $6.11M | 2.1% | +1,421,501 | New | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 600,000 | $6.18M | 2.2% | +115,000+23.7% | Added | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 235,000 | $6.39M | 2.2% | −65,000−21.7% | Reduced | History |
| IMVTImmunovant, Inc. | COM | 260,000 | $6.86M | 2.4% | +135,000+108.0% | Added | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 350,000 | $7.19M | 2.5% | +200,000+133.3% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 587,708 | $7.65M | 2.7% | −37,292−6.0% | Reduced | History |
| CRBPCorbus Pharmaceuticals Holdings, Inc. | COM NEW | 175,000 | $7.92M | 2.8% | +118,059+207.3% | Added | History |
| CGONCG Oncology, Inc. | COM | 260,000 | $8.21M | 2.9% | +185,000+246.7% | Added | History |
| SRPTSarepta Therapeutics, Inc. | COM | 55,000 | $8.69M | 3.0% | −70,000−56.0% | Reduced | History |
| TGTXTG Therapeutics, Inc. | COM | 500,000 | $8.89M | 3.1% | −325,000−39.4% | Reduced | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 925,000 | $9.22M | 3.2% | +925,000 | New | History |
| ROIVRoivant Sciences Ltd. | SHS | 1,000,000 | $10.6M | 3.7% | −300,000−23.1% | Reduced | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 240,000 | $10.7M | 3.7% | +40,000+20.0% | Added | History |
| PCVXVaxcyte, Inc. | COM | 150,000 | $11.3M | 3.9% | +55,000+57.9% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 86,721 | $11.8M | 4.1% | +86,721 | New | History |
| AXSMAxsome Therapeutics, Inc. | COM | 150,000 | $12.1M | 4.2% | −60,000−28.6% | Reduced | History |
| SLNOSoleno Therapeutics Inc | COM | 300,000 | $12.2M | 4.3% | +100,000+50.0% | Added | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 300,000 | $13.2M | 4.6% | 00.0% | Unchanged | History |
| BHVNBiohaven Ltd. | COM | 490,000 | $17.0M | 5.9% | +205,000+71.9% | Added | History |
Options (4)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q1 2024 (18)
Positions held at the end of Q1 2024 that are gone from this filing.
| Security | Class | Shares in Q1 2024 | Value in Q1 2024 | % of portfolio in Q1 2024 | History |
|---|---|---|---|---|---|
| CATXPerspective Therapeutics, Inc. | COM | 6,000,000 | $7.14M | 2.3% | History |
| JBIOJade Biosciences, Inc. | COM | 225,000 | $6.65M | 2.1% | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 75,000 | $3.21M | 1.0% | History |
| COGTCogent Biosciences, Inc. | COM | 450,000 | $3.02M | 1.0% | History |
| AQSTAquestive Therapeutics, Inc. | COM | 702,941 | $2.99M | 1.0% | History |
| DCPHDeciphera Pharmaceuticals, Inc. | COM | 176,513 | $2.78M | 0.9% | History |
| GERNGeron Corp | COM | 800,000 | $2.64M | 0.8% | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 285,000 | $2.58M | 0.8% | History |
| ALTAltimmune, Inc. | COM NEW | 250,000 | $2.54M | 0.8% | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 200,000 | $2.37M | 0.8% | History |
| NTRANatera, Inc. | COM | 25,000 | $2.29M | 0.7% | History |
| PTGXProtagonist Therapeutics, Inc | COM | 75,000 | $2.17M | 0.7% | History |
| EYPTEyePoint, Inc. | COM NEW | 90,000 | $1.86M | 0.6% | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 6,500 | $1.74M | 0.6% | History |
| ATXSAstria Therapeutics, Inc. | COM | 115,000 | $1.62M | 0.5% | History |
| LRMRLarimar Therapeutics, Inc. | COM | 210,603 | $1.60M | 0.5% | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 20,000 | $933.8K | 0.3% | History |
| QUREuniQure N.V. | SHS | 165,000 | $858.0K | 0.3% | History |